NEW YORK – Precision immunology firm Scipher Medicine said on Wednesday that it has entered a collaboration with Galapagos to advance novel drug targets it has identified in analysis of molecular data from patients with inflammatory bowel disease (IBD).
The two companies will jointly validate a set of novel targets that Scipher has discovered using what it calls its Network Medicine Platform, a process that employs artificial intelligence methods and information about protein interaction networks, uncovering potentially druggable pathways and/or therapy-predictive biomarkers.